Dr. Reddy’s Laboratories reports a sharp decline in its consolidated fourth-quarter performance for the quarter ended March 31, 2026. The company’s profit after tax (PAT) falls 86% to ₹221.3 crore, compared with ₹1,586.7 crore in the same quarter of the previous fiscal year. In the quarter, consolidated revenue from operations declines to ₹7,546.4 crore from ₹8,528.4 crore a year earlier.
The company attributes the fall mainly to weaker generics sales in North America, where generics revenue drops 51% to ₹1,756.2 crore from ₹3,558.6 crore year-on-year. By contrast, generics revenue in India rises 20% to ₹1,566.3 crore, up from ₹1,304.7 crore in the year-ago quarter. Generics revenue in Europe also increases by 14% to ₹1,452 crore from ₹1,275 crore in the previous year.
The Hindu also notes that multiple one-off items contribute to the year-on-year drop, with the company preparing results as per Indian Accounting Standards (Ind AS).
